Comprehensive molecular profiling of 5,175 esophagogastric cancer (EGC) patients identified distinct molecular signatures for early-onset (< 50 years of age, EOEGC, n=530) versus average-onset (AOEGC, n=4,645) tumors.
EOEGC has increased frequency of CDH1 mutations, ARHGAP26 fusions, enrichment of epithelial mesenchymal transition (EMT) and angiogenesis pathways, decreased MAPK pathway activity, decreased frequency of TMB-high and dMMR/MSI-H, and a unique immune cell infiltrate with decreased M1 macrophages and increased M2 macrophages.
These unique differential characteristics present therapeutic opportunities but also demonstrate the limitations of currently approved therapies in this subset of patients.
Abstract Somatostatin receptor 2 is expressed in nasopharyngeal carcinoma (NPC). We report genomic and transcriptomic analysis results of 163 NPC cases, demonstrating that somatostatin receptor… […]
Molecular and clinical correlates of high FOLH1 (PSMA) RNA expression in primary and metastatic prostate cancer
Abstract Background: Prostate-specific membrane antigen (PSMA; FOLH1) is a cell-surface target for diagnostics and treatment in prostate cancer. We utilized a database of molecularly-profiled prostate tumors… […]
